{"id":"trimbow-pmdi","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Dysphonia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The inhaled corticosteroid reduces airway inflammation and mucus production. The long-acting beta-2 agonist and long-acting muscarinic antagonist work synergistically to relax bronchial smooth muscle through different pathways, providing sustained bronchodilation. This triple combination addresses multiple pathophysiological mechanisms in COPD to improve airflow and reduce exacerbations.","oneSentence":"Trimbow combines three active ingredients—beclomethasone dipropionate (inhaled corticosteroid), formoterol fumarate (long-acting beta-2 agonist), and glycopyrronium (long-acting muscarinic antagonist)—to reduce airway inflammation and improve bronchial smooth muscle relaxation in chronic obstructive pulmonary disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:41.901Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT03963167","phase":"","title":"Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)","status":"COMPLETED","sponsor":"Chiesi Italia","startDate":"2019-08-21","conditions":"COPD","enrollment":661},{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":"Asthma","enrollment":20},{"nctId":"NCT07406048","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB Extrafine in a Single Pressurised Metered Dose Inhaler in Brazilian COPD Patients","status":"NOT_YET_RECRUITING","sponsor":"Chiesi Farmaceutica Ltda.","startDate":"2026-01-30","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":396},{"nctId":"NCT06480890","phase":"","title":"Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients (TRIPHY)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2024-07-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":362},{"nctId":"NCT04902573","phase":"","title":"A Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extrafine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Out-comes","status":"COMPLETED","sponsor":"Chiesi UK","startDate":"2021-06-17","conditions":"Asthma","enrollment":147},{"nctId":"NCT06234345","phase":"PHASE3","title":"Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)","status":"NOT_YET_RECRUITING","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1252},{"nctId":"NCT06678191","phase":"","title":"Investigation of Fixed Triple Inhaled Combination in Asthmatic Patients, in a Real-life Setting","status":"RECRUITING","sponsor":"Chiesi Hungary Ltd.","startDate":"2024-10-24","conditions":"Asthma, Chronic Obstructive Pulmonary Disease (COPD), Asthma Bronchiale","enrollment":800},{"nctId":"NCT05898984","phase":"PHASE1","title":"Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-04-24","conditions":"Asthma","enrollment":69},{"nctId":"NCT06571942","phase":"PHASE4","title":"Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure","status":"RECRUITING","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2023-11-15","conditions":"COPD Bronchitis, Pollution Related Respiratory Disorder","enrollment":128},{"nctId":"NCT04355546","phase":"","title":"Non-interventional Study Related to Fixed LAMA/LABA/ICS Triple Therapy","status":"COMPLETED","sponsor":"Chiesi UK","startDate":"2020-07-15","conditions":"COPD","enrollment":94},{"nctId":"NCT05728749","phase":"","title":"A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes","status":"UNKNOWN","sponsor":"Chiesi SAS","startDate":"2023-03-03","conditions":"ASTHMA","enrollment":300},{"nctId":"NCT05097014","phase":"PHASE4","title":"CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-10-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":106},{"nctId":"NCT03795350","phase":"PHASE1","title":"Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2019-01-14","conditions":"Chronic Obstructive Pulmonary Disease, Asthma","enrollment":19},{"nctId":"NCT04671355","phase":"PHASE4","title":"TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD","status":"WITHDRAWN","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-10-04","conditions":"COPD","enrollment":""},{"nctId":"NCT03842904","phase":"PHASE4","title":"A Study Comparing the Effects of Trimbow to Fostair in COPD","status":"COMPLETED","sponsor":"Medicines Evaluation Unit Ltd","startDate":"2018-12-13","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Trimbow pMDI","genericName":"Trimbow pMDI","companyName":"Medicines Evaluation Unit Ltd","companyId":"medicines-evaluation-unit-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trimbow combines three active ingredients—beclomethasone dipropionate (inhaled corticosteroid), formoterol fumarate (long-acting beta-2 agonist), and glycopyrronium (long-acting muscarinic antagonist)—to reduce airway inflammation and improve bronchial smooth muscle relaxation in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}